Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs

By Christine Filippis / October 1, 2024
Financing round was significantly oversubscribed by existing investors and new private investors. Funding will enable the Company to progress clinical...
Read More

Cartherics’ CEO named ScholarGPS highly ranked scholar for outstanding scholarly contributions

By Christine Filippis / September 20, 2024
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar...
Read More

Breakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment

By Christine Filippis / August 8, 2024
Exciting advancements are on the horizon for cancer treatment. Earlier this year, the FDA approved Lifileucel, an autologous tumor infiltrating...
Read More
1 2 3 60